Discovery of Novel Anti-Diabetic Drugs by Targeting Lipid Metabolism

Author(s): Xiu Zhou, Jun Xu, Yuguang Shi, Ji-Ming Ye

Journal Name: Current Drug Targets

Volume 16 , Issue 12 , 2015

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Accumulation of toxic lipids is the most common etiology of insulin resistance in type 2 diabetes and associated metabolic disorders such as obesity and non-alcoholic fatty liver disease. Understanding of the underlying mechanisms has revealed various opportunities to target key regulators in lipid metabolic pathways for the treatment of metabolic diseases. Here, we review the discovery and development of potential anti-diabetic drugs with primary effects on cellular targets leading to reductions of intracellular lipids in key organs. We will particularly focus on AMPK, SIRT1, PGC-1α, SREBP-1c, ChREBP, ACC, PPARs and HSPs which either stimulate in fatty acid oxidation (energy expenditure) or inhibit de novo lipogenesis.

Keywords: Anti-diabetic drug targets, drug discovery, insulin resistance, lipid metabolism.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Published on: 13 October, 2015
Page: [1372 - 1380]
Pages: 9
DOI: 10.2174/1389450116666150223120829
Price: $65

Article Metrics

PDF: 46